Pharmacotherapy for weight reduction in type 2 diabetes*
| Comparisons | Outcomes | Follow up | Number of trials (n) | Weighted mean difference (95% CI) |
|---|---|---|---|---|
| *GHb = glycated haemoglobin. CI defined in glossary; data were pooled using a random effects model. Differences favour the active drug. †Not significant. | ||||
| Fluoxetine v placebo | Weight (kg) | 8–16 wks | 5 (192) | −3.4 (−5.2 to −1.7) |
| Weight (kg) | 24–30 wks | 4 (97) | −5.1 (−6.9 to −3.3) | |
| GHb | 8–16 wks | 4 (145) | −1.0% (−1.5 to −0.4) | |
| GHb | 24–30 wks | 4 (97) | −1.0% (−1.4 to −0.6) | |
| Orlistat v placebo | Weight (kg) | 52–57 wks | 3 (818) | −2.6 (−3.2 to −2.1) |
| GHb | 52–57 wks | 4 (904) | −0.4% (−0.5 to −0.3) | |
| Sibutramine v placebo | Weight (kg) | 12–26 wks | 4 (391) | −4.5 (−7.2 to −1.8) |
| GHb | 12–26 wks | 4 (368) | −0.7% (−1.9 to 0.5)† | |